|RFx ID :||25820806|
|Tender Name :||Future Procurement Opportunity (FPO) – Supply of immune checkpoint inhibitors for the treatment of locally advanced/metastatic non-small cell lung cancer|
|Reference # :|
|Open Date :||Q2 2022|
|Indicative RFx Release Date :||Q3 2022 [?]|
|Tender Type :||Future Procurement Opportunity (FPO)|
|Project Status :||Awaiting approval [?]|
|Indicative Total Value :||$100M + [?]|
|Tender Coverage :||Sole Agency [?]|
|Required Pre-qualifications :||None|
Pharmac Procurement Team
Pharmac will issue a competitive process for supply of immune checkpoint inhibitors (ICI’s) for the treatment of locally advanced/metastatic non-small cell lung cancer (NSCLC).
The anticipated outcome is a scenario where one or more ICI products would be awarded a period of Principal Supply exclusivity for listing in the Pharmaceutical Schedule, for one or more of the predefined patient groups; patients receiving ICIs for:
- first line 1L monotherapy;
- first line 1L combination therapy;
- second line 2L therapy.